Page 420 - Binder2

gatekeeping, and complex reimbursement processes all
serve as filters.

But edible biologics dismantle those filters.
They can be:

• Grown affordably.
• Stabilized without refrigeration.
• Shipped without oversight.
• Taken without a clinician present.

This redefines the ethics of affordability. It’s no longer a
downstream concern—it’s a design variable.

When drugs are:

• Cheap to produce,
• Easy to store,
• Safe to use,
…then access is no longer a charity.
It’s a structural default.

The ethical imperative shifts from "expand access" to:

Design access in.

This is not about market generosity.
It’s about moral architecture.
And in that architecture, open-source licensing, community
manufacturing, and equity-centered scale are not
idealistic—they are required.

418